Keywords: atacand, cuts, mortality, stroke, patients, astrazeneca, angiotensin
Atacand cuts mortality in stroke patients
Article | 06 December 2001
AstraZeneca's angiotensin II receptor antagonist Atacand (candesartancilexetil) has been shown to reduce total mortality, cerebral complications and cardiovascular complications in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
